Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03557281
Recruitment Status : Suspended (Due to the COVID-19 pandemic, this study has temporarily suspended recruitment activities. Other elements of the study are ongoing.)
First Posted : June 15, 2018
Last Update Posted : April 22, 2020
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
Tuberculosis remains a concerning health problem, with Mycobacterium Tuberculosis (MTB) now causing more deaths than acquired immune deficiency syndrome (AIDS). GSK3036656 is a compound with a novel mechanism of action under development for the treatment of tuberculosis. It suppresses protein synthesis in MTB by selectively inhibiting the enzyme Leucyl t-ribose nucleic acid (RNA) synthetase. Thus, this study will investigate the early bactericidal activity, safety and tolerability of GSK3036656 in up to four sequential cohorts of subjects with rifampicin-susceptible tuberculosis. The primary objective of this dose-escalation study is to establish the anti-tuberculosis effect of GSK3036656 on serial colony forming units (CFU) counts of MTB in sputum over 14 days of therapy. Subjects in each cohort will be randomized in 3:1 ratio to one of two treatments: either GSK3036656 or standard-of-care (RIFAFOUR® e-275) regimen. The approximate duration of the study for an individual subject will be 5 weeks, including 1 week of screening, 2 weeks of treatment period and another 2 weeks of final follow-up visit. RIFAFOUR e-275 is a registered trademark of Sanofi-Aventis.

Condition or disease Intervention/treatment Phase
Tuberculosis Drug: GSK3036656 Drug: RIFAFOUR e-275 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Eligible subjects in each cohort will be randomized to receive sequential doses of either GSK3036656 or standard-of-care (RIFAFOUR) regimen. This study will employ dose escalation, where the decision to proceed to each subsequent dose level will be made based on safety, tolerability and preliminary pharmacokinetic data from the prior cohort.
Masking: None (Open Label)
Masking Description: This will be an open label study. Hence, there will be no masking.
Primary Purpose: Treatment
Official Title: A Phase IIa Open-label Trial to Investigate the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Participants With Drug-sensitive Pulmonary Tuberculosis
Actual Study Start Date : March 22, 2019
Estimated Primary Completion Date : February 15, 2022
Estimated Study Completion Date : February 15, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arm Intervention/treatment
Experimental: Subjects receiving GSK3036656
Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
Drug: GSK3036656
GSK3036656 will be available as an oral capsule with dosing strengths of 1 milligrams or 5 milligrams or 25 milligrams.

Active Comparator: Subjects receiving RIFAFOUR e-275
Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
Drug: RIFAFOUR e-275
RIFAFOUR will be available as an oral tablet with a standard dose of 150/75/400/275 milligrams of rifampicin, isoniazid, pyrazinamide and ethambutol per tablet respectively.




Primary Outcome Measures :
  1. Rate of change in log10 CFU per milliliter direct respiratory sputum samples from Baseline to Day 14 [ Time Frame: Baseline and up to day 14 ]
    The early bactericidal activity of GSK3036656 will be determined as the rate of change in log10 CFUs of MTB in sputum.


Secondary Outcome Measures :
  1. Number of subjects with adverse events and serious adverse events [ Time Frame: Up to 28 days ]
    An adverse event is any untoward medical occurrence in a clinical study subjects, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward medical occurrence resulting in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as serious adverse event.

  2. Number of subjects with abnormal findings for clinical chemistry parameters [ Time Frame: Up to 28 days ]
    Blood samples will be collected from subjects for the analysis of clinical chemistry parameters as a measure of safety, including blood urea nitrogen, potassium, aspartate aminotransferase, total bilirubin, indirect bilirubin, direct bilirubin, albumin, creatinine, sodium, alanine aminotransferase, gamma-glutamyl transferase, lactate dehydrogenase, sodium, potassium, calcium (corrected for albumin), chloride, total protein, glucose (random/fasting) and alkaline phosphatase.

  3. Number of subjects with abnormal findings for hematology parameters [ Time Frame: Up to 28 days ]
    Blood samples will be collected from subjects for the analysis of hematology parameters as a measure of safety, including platelet count, mean corpuscular volume, mean corpuscular hemoglobin, percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's, basophils, red blood cells count, hemoglobin, and hematocrit coagulation test.

  4. Number of subjects with abnormal findings for urinalysis parameters [ Time Frame: Up to 28 days ]
    Urine samples will be collected from subjects for the analysis of urinalysis parameters as a measure of safety, including specific gravity and potential of hydrogen (pH) of urine, presence of glucose, protein, blood, micro-albumin, creatinine, nitrite, ketones, bilirubin, urobilinogen, sodium and leukocytes in urine by dipstick test. Microscopic examination will be performed if blood or protein is abnormal.

  5. Number of subjects with abnormal values for blood pressure [ Time Frame: Up to 28 days ]
    Systolic and diastolic blood pressure of subjects will be measured in a semi-supine or supine position after at least 5 minutes of rest.

  6. Number of subjects with abnormal values for respiratory rate [ Time Frame: Up to 28 days ]
    Respiratory rate of subjects will be measured in a semi-supine or supine position after at least 5 minutes of rest.

  7. Number of subjects with abnormal values for pulse rate [ Time Frame: Up to 28 days ]
    Pulse rate of subjects will be measured in a semi-supine or supine position after at least 5 minutes of rest.

  8. Number of subjects with abnormal values for oral temperature [ Time Frame: Up to 28 days ]
    Oral temperature of subjects will be measured in a semi-supine position after at least 5 minutes of rest.

  9. Number of subjects with abnormal values for electrocardiogram parameters [ Time Frame: Up to 28 days ]
    Single 12-lead electrocardiogram will be obtained using an electrocardiogram machine.

  10. Area under the plasma drug concentration versus time curve from time zero to last time of quantifiable concentration (AUC [0-t]) following once daily dosing of GSK3036656 [ Time Frame: Pre-dose on Day 12 and Day 13; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 14; and 24 hours post-dose on Day 15 ]
    Blood samples will be collected for pharmacokinetic analysis of GSK3036656.

  11. Area under the plasma concentration time curve from zero to end of dosing interval (AUC [0-24]) following once daily dosing of GSK3036656 [ Time Frame: Pre-dose on Day 12 and Day 13; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 14; and 24 hours post-dose on Day 15 ]
    Blood samples will be collected for pharmacokinetic analysis of GSK3036656.

  12. Maximum observed plasma drug concentration (Cmax) following once daily dosing of GSK3036656 [ Time Frame: Pre-dose on Day 12 and Day 13; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 14; and 24 hours post-dose on Day 15 ]
    Blood samples will be collected for pharmacokinetic analysis of GSK3036656.

  13. Time to reach Cmax (Tmax) following once daily dosing of GSK3036656 [ Time Frame: Pre-dose on Day 12 and Day 13; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 14; and 24 hours post-dose on Day 15 ]
    Blood samples will be collected for pharmacokinetic analysis of GSK3036656.

  14. Rate of change in log10 CFU per milliliter direct respiratory sputum samples from Baseline to Day 2 [ Time Frame: Baseline and up to Day 2 ]
    The early bactericidal activity of GSK3036656 will be determined as the rate of change in log10 CFUs of MTB in sputum.

  15. Rate of change in log10 CFU per milliliter direct respiratory sputum samples from Day 2 to Day 14 [ Time Frame: Day 2 and up to Day 14 ]
    The early bacterial activity of GSK3036656 will be determined as the rate of change in log10 CFUs of MTB in sputum.

  16. Rate of change in time to sputum culture positivity from Baseline to Day 14 [ Time Frame: Baseline and up to Day 14 ]
    The early bacterial activity of GSK3036656 will be determined as the rate of change in log10 CFUs of MTB in sputum.

  17. Rate of change in time to sputum culture positivity from Baseline to Day 2 [ Time Frame: Baseline and up to Day 2 ]
    The early bacterial activity of GSK3036656 will be determined as the rate of change in time to sputum culture positivity of MTB in sputum.

  18. Rate of change in time to sputum culture positivity over the time period from Day 2 to Day 14 [ Time Frame: Day 2 and up to Day 14 ]
    The early bacterial activity of GSK3036656 will be determined as the rate of change in time to sputum culture positivity of MTB in sputum.

  19. Change from Baseline in QT interval corrected using Fridericia's formula (QTcF) [ Time Frame: Baseline and up to Day 14 ]
    The exposure-response relationship between GSK3036656 and QTcF following repeated administration will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
  • In addition, subjects recruited into cohorts that are planned to undergo fluorodeoxyglucose (FDG) positron emission tomography/ Computed Tomography (PET/CT) must be >=25 years of age, at the time of signing the informed consent.
  • New episode of untreated, rifampicin-susceptible pulmonary tuberculosis.
  • A chest X-ray picture which in the opinion of the Investigator is consistent with tuberculosis.
  • At least one sputum sample positive on direct microscopy for acid-fast bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease/ World Health Organization [IUATLD/WHO] scale) or molecular test (Xpert MTB/ rifampicin) with result of either medium or high positive for MTB: Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 milliliter or more); estimated from a spot sputum sample at screening; confirmed at the first overnight collection; if less than 10 milliliter is collected overnight this may be repeated once.
  • Normal echocardiogram or echocardiogram with normal left ventricular function with at most trace to mild valvular regurgitation and no valvular stenosis.
  • Within the normal range for the assay for troponin and b-type natriuretic peptide at screening.
  • Body weight (in light clothing and with no shoes) between 40 and 90 kilograms, inclusive, at screening.
  • Male or female of non-childbearing potential will be included in the study. A male subject with female partners of child-bearing potential must agree to use contraception during the treatment period and for at least 6 weeks, corresponding to time needed to eliminate study treatment plus an additional 90 days (a spermatogenesis cycle) for study treatments with teratogenic potential after the last dose of study treatment and refrain from donating sperm during this period. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Pre-menopausal females with one of the following; documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion or documented bilateral salpingectomy; hysterectomy; documented Bilateral Oophorectomy. Postmenopausal will be defined as 12 months of spontaneous amenorrhea without an alternative medical cause. Post-menopausal status will be confirmed by a simultaneous follicle-stimulating hormone and estradiol levels test.
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • Evidence of a clinically significant (as judged by the Investigator) condition or abnormality (other than the indication being studied) that might compromise safety or the interpretation of trial efficacy or safety endpoints.
  • Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator.
  • A previous episode of treated tuberculosis less than 3 years ago.
  • Clinically significant evidence of extrathoracic tuberculosis (miliary tuberculosis, abdominal tuberculosis, urogenital tuberculosis, osteoarthritic tuberculosis, tuberculosis meningitis), as judged by the Investigator.
  • Corrected QT Interval > 450 milliseconds.
  • History of allergy to any of the trial investigational product/s or related substances as confirmed by the clinical judgement of the Investigator.
  • History of photosensitivity.
  • Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the subject.
  • HIV infected subjects: having a cluster of differentiation 4+ (CD4+) count <350 cells per microliter; or having received antiretroviral therapy medication within the last 90 days; or having received oral or intravenous antifungal medication within the last 90 days; or with an AIDS-defining opportunistic infection or malignancies (except pulmonary tuberculosis).
  • Participated in other clinical studies with investigational agents within 8 weeks prior to the first dosing day in the current study.
  • Subjects with diabetes (Type 1 or 2), point of care glycated hemoglobin above 6.5 millimoles per mole, or random glucose over 11.1 millimoles per liter will be excluded from cohorts undergoing FDGPET/CT. Subjects not undergoing FDG-PET/CT will be excluded if they have unstable diabetes or insulin dependency.
  • Treatment received with any drug active against MTB (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides, metronidazole), or with immunosuppressive medications such as tumor necrosis factor -alpha inhibitors or systemic or inhaled corticosteroids, within 2 weeks prior to screening.
  • Subjects with the following abnormal laboratory values at screening as defined by the enhanced Common Terminology Criteria for Adverse Events toxicity table: creatinine grade 2 or greater (>1.5 times upper limit of normal [ULN]); hemoglobin <10.0 grams per deciliter; thrombocytopenia grade 2 or greater (under 50 times 10^9 cells per liter); serum potassium grade 2 or greater (<3.0 milliequivalents per liter); aspartate aminotransferase grade 3 (>=3.0 times ULN); alanine aminotransferase grade 3 (>=3.0 times ULN); activated partial thromboplastin time grade 3 (>=2.5 times ULN); international normalized ratio grade 3 (>=2.5 times ULN); total white cell count grade 3 (<2.0 times 10^9 cells per liter).
  • Subjects who are selected to undergo FDG-PET/CT who have been estimated to have been exposed to ionizing radiation in excess of 10 millisievert above background over the previous three-year period as a result of occupational exposure to radiation or as a result of research studies. This will be judged through clinical history taking.
  • Women who are susceptible to heavy periods or heavy vaginal bleeding or spotting will be excluded in order to minimize blood loss and avoid confounding effects on the interpretation of hematology parameters.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03557281


Locations
Layout table for location information
South Africa
GSK Investigational Site
Cape Town, South Africa, 7530
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03557281    
Other Study ID Numbers: 201214
First Posted: June 15, 2018    Key Record Dates
Last Update Posted: April 22, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GlaxoSmithKline:
Early bactericidal activity
Mycobacterium Tuberculosis
GSK3036656
Pulmonary tuberculosis
Colony forming units
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Tuberculosis, Pulmonary
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections